Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCL
May 23rd 2023Hun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
Watch